- Home
- ZENA vs KLRS Comparison
ZENA vs KLRS Comparison
Compare ZENA & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- KLRS
- Stock Information
- Founded
- ZENA 2017
- KLRS 2019
- Country
- ZENA Canada
- KLRS United States
- Employees
- ZENA N/A
- KLRS N/A
- Industry
- ZENA
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENA
- KLRS Health Care
- Exchange
- ZENA NYSE
- KLRS Nasdaq
- Market Cap
- ZENA 109.4M
- KLRS 129.0M
- IPO Year
- ZENA N/A
- KLRS N/A
- Fundamental
- Price
- ZENA $3.59
- KLRS $2.64
- Analyst Decision
- ZENA Strong Buy
- KLRS Buy
- Analyst Count
- ZENA 1
- KLRS 1
- Target Price
- ZENA $9.00
- KLRS N/A
- AVG Volume (30 Days)
- ZENA 10.0M
- KLRS 43.0K
- Earning Date
- ZENA 01-01-0001
- KLRS 08-15-2025
- Dividend Yield
- ZENA N/A
- KLRS N/A
- EPS Growth
- ZENA N/A
- KLRS N/A
- EPS
- ZENA N/A
- KLRS N/A
- Revenue
- ZENA $1,744,794.00
- KLRS N/A
- Revenue This Year
- ZENA N/A
- KLRS N/A
- Revenue Next Year
- ZENA N/A
- KLRS N/A
- P/E Ratio
- ZENA N/A
- KLRS N/A
- Revenue Growth
- ZENA 24.50
- KLRS N/A
- 52 Week Low
- ZENA $1.41
- KLRS $2.28
- 52 Week High
- ZENA $12.43
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- KLRS N/A
- Support Level
- ZENA N/A
- KLRS N/A
- Resistance Level
- ZENA N/A
- KLRS N/A
- Average True Range (ATR)
- ZENA 0.00
- KLRS 0.00
- MACD
- ZENA 0.00
- KLRS 0.00
- Stochastic Oscillator
- ZENA 0.00
- KLRS 0.00
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The company operates in software development technology, sales, and distribution. The company is also developing a drone manufacturing, sales, and distribution business. It generates revenue from software licensing and subscription agreements, software support and maintenance, and technology consulting services.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.